Abstracts tagged "MSCs"

Abstract Number: 857 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients
Xinran Yuan ¹, Dandan Wang ¹ and Lingyun Sun², ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic)
Background/Purpose: Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely…
Abstract Number: 1054 • 2018 ACR/ARHP Annual Meeting
Study of the Metabolic Effect of MSCs on Their Chondroprotective and Regenerative Properties: Modulating Their Metabolism to Improve Their Therapeutic Potential for the Treatment of Osteoarthritis
Luna Martinez-Viola¹, Patricia Luz-Crawford² and Rafael A. Contreras², ¹Laboratorio de Inmunología Celular y Molecular, Universidad de Los Andes, Santiago, Chile, ²Inmunology, Universidad de Los Andes, Santiago, Chile
Background/Purpose: Mesenchymal Stem Cells (MSCs) are stromal multipotent cells with wide regenerative and immunomodulatory properties and have been proposed as a powerful therapeutic tool. Among…
Abstract Number: 2111 • 2018 ACR/ARHP Annual Meeting
Ifnβ Affects Osteogenesis-Adipogenesis Axis in SLE Bone Marrow
Lin Gao, Mary O'Connell, Jennifer Anolik and R. John Looney, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: SLE patients are especially vulnerable to corticosteroid induced avascular necrosis. While it is appreciated that multiple factors contribute to AVN, the bone-fat axis in…
Abstract Number: 1655 • 2017 ACR/ARHP Annual Meeting
Interferon b Blockade Rescues Human BM-MSC Osteoblastogenesis Defects in Systemic Lupus Erythematosus
Lin Gao¹, Jennifer H. Anolik² and R. John Looney³, ¹medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow mesenchymal stromal cells (BM-MSCs) are multipotent stem cells that can differentiate into chondrocytes, osteoblasts and adipocytes. SLE has been implicated as a…
Abstract Number: 310 • 2016 ACR/ARHP Annual Meeting
A Novel One Stage Technique Applicable during Arthroscopy for the Mobilization of Synovial Mesenchymal Stromal Cells Towards Joint Regeneration
Alam Khalil-Khan¹, Thomas Baboolal², Elena Jones³, Owen Wall⁴ and Dennis McGonagle³, ¹Faculty of Medicine, Leeds institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, ²PhD, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Orthopaedic Surgery, Department of Trauma and Orthopaedics, Leeds, United Kingdom
Background/Purpose: , The discovery of MSCs in the synovium and synovial fluid (SF) provided a potential mechanism for repairing cartilage “from the top down”. Indeed,…
Abstract Number: 1102 • 2016 ACR/ARHP Annual Meeting
Differentiation of Spongiosa-Derived Mesenchymal Stromal Cells from Osteoporosis and Osteoarthritis Patients Are Influenced By Adipokines
Lali Tsiklauri¹, Janina Werner², Klaus W. Frommer¹, Ulf Müller-Ladner³, Stefan Rehart⁴, Sabine Wenisch² and Elena Neumann¹, ¹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad Nauheim, Germany, ²Justus-Liebig-University Giessen, Institute of Veterinary-Anatomy, -Histology and –Embryology, Clinic of Small Animals, Giessen Germany, Giessen, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁴Orthopedic & Trauma Surgery, Agaplesion Markus-Hospital, Frankfurt, Frankfurt, Germany
Background/Purpose: Osteoporosis is characterized by bone loss, increased fracture risk and reduced regeneration ability. Age-related bone loss leading to osteoporosis correlates with increased bone marrow…
Abstract Number: 1103 • 2016 ACR/ARHP Annual Meeting
Gingival Tissue-Derived MSC Cells (GMSC) Suppress Osteoclastogenesis and Bone Erosion in Collagen-Induced Arthritis Thought CD73 Signal Pathway
Yongjiang Zheng^1,2, Julie Wang³, Nancy J. Olsen⁴, Limin Rong¹ and Song Guo Zheng^4,5, ¹Center for Clinic Immunology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, ²Medicine, Penn State University Hershey Medical Center, Hershey, PA, ³Medicine, Penn State Hershey Medical Center, Hershey, PA, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Medicine/Rheumatology, Penn State University Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory synovitis leading to joint destruction and systemic bone loss. Osteoclasts are responsible for bone destruction in…
Abstract Number: 1377 • 2015 ACR/ARHP Annual Meeting
IL-22 Drives the Proliferation and Differentiation of Human Bone Marrow Mesenchymal Stem Cells (MSCs); A Novel Pathway That May Contribute to Aberrant New Bone Formation in Human Spa and Beyond
Yasser El-Sherbiny¹, Ahmed Elzayadi², Evangelos M. Fragkakis¹, Richard Cuthbert¹, Thomas Baboolal³, Elena Jones¹ and Dennis McGonagle¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Obstetrics and Gynaecology, Mansoura University, Egypt, MD, MSc., Mansoura, Egypt, ³PhD, Leeds, United Kingdom
Background/Purpose: The human spondyloarthropathies (SpA) are associated with single nucleotide polymorphisms (SNPs) in the IL-23 pathway and IL-23/17 axis therapy is effective in SpA. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].